资源描述:
《前列地尔脂微球载体注射液对老年下肢动脉血管病变患者血小板活化功能的影响》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库。
1、前列地尔脂微球载体注射液对老年下肢动脉血管病变患者血小板活化功能的影响作者:冯淑芝孙宁曹丽田建立陈珺【摘要】目的探讨前列地尔脂微球载体注射液对老年下肢动脉血管病变患者血小板活化功能的影响。方法选择老年下肢动脉血管病变患者120例,随机分为对照组(60例)和治疗组(60例)。对照组每日给予银杏叶提取物注射液70mg/d溶解在250ml生理盐水中静脉滴注,连续使用14d,治疗组采用前列地尔脂微球载体注射液20μg/d溶解在20ml生理盐水中静脉慢推,连续治疗14d,观察两组患者治疗前后的症状、股动脉、腘动脉、胫后动脉、足背动脉内径及血流量的变
2、化,并测定血糖、血脂、肝酶、肾功能、血小板α颗粒膜糖蛋白140、血小板CD62p和CD63以及前列环素、血栓素。结果治疗组治疗后老年下肢动脉血管病变患者症状明显改善,股动脉、腘动脉、胫后动脉、足背动脉内径及血流量均有所增加,血小板膜α颗粒糖蛋白140、CD62p、CD63以及前列环素、血栓素有所下降(P<0.05),其他生化指标无明显变化(P>0.05)。结论前列地尔脂微球载体注射液可以降低老年下肢动脉血管病变患者血小板的活化功能,有效改善其症状,安全用于老年患者的治疗。【关键词】前列地尔脂微球载体注射液;老年人;下肢动脉血管;血小板
3、活化功能9 【Abstract】ObjectiveToassesstheinfectionofLiposomalprostaglandinE1(LipoPGE1)onhematoblasticactivationfunctionwithlowerlimbarterialbloodvesseldiseaseingeriatrics.Methods120patientswithlowerlimbbloodarterialvesseldiseasewererandomlydividedintocontrolandtreatmentgroup
4、s.PatientsintreatmentgroupwereadministeredwithLipoPGE1(20μg/d)for14days,patientsincontrolgroupwereadministeredwithGinkgoBilobaLeafExtract(70mg/d)for14days.Clinicalsymptomwasobserved,vasculardiameterandbloodflowvelocityoffemoralartery,poplitealartery,posteriortibialartery
5、anddorsalpedalarterywereevaluatedbyDoppleruitrasonographyexamination,bloodglucoselevel,bloodlipidlevel,peptase,renalfunction,αgranulemembraneprotein(GMP140),hematoblasticCD62pandCD63,6ketoneprostacyclin(6kPGF1α),thromboxaneB2(TXB2)weremeasuredpreandposttreatment.R
6、esultsAftergivenLipoPGE1posttreatment,theclinicalsymptomsandsignshadbeenmendedinthepatientswithlowerlimbarterialbloodvesseldisease,vasculardiameterandbloodflowvelocityoffemoralartery,poplitealartery,posteriortibialarteryanddorsalpedalarterywereincreased,however,therewere
7、no9significantlydifferences.GMP140,CD62p,CD63,6kPGF1α,TXB2weredecreased,andthereweresignificantdifferencesbetweencontrolandtreatmentgroups(P<0.05).Theotherindicatorsdidnotchange,therewerenosignificantdifferences(P>0.05).ConclusionsLipoPGE1caninhibitehematoblasticac
8、tivationfunction,improvethesymptomwithlowerlimbarterialbloodvesseldisease,whichissafetosenilepat